Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,880.41 +1,619.57 (+2.48%) CMC Crypto 200
1,364.93 -8.91 (-0.65%)
SLNO May 2024 45.000 put
| Previous close | 0.5900 |
| Open | 0.5900 |
| Bid | 0.0000 |
| Ask | 2.9500 |
| Strike | 45.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.5900 - 0.5900 |
| Contract range | N/A |
| Volume | |
| Open interest | 42 |
GlobeNewswireSoleno Therapeutics Stands with the Prader-Willi Syndrome Community
This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi syndrome communityREDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today launched a groundbreaking initiative in honor of Prader-Willi Syndrome (PWS) Awareness Day. The campaign
- GlobeNewswire
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 and Recent Corporate Highlights Closed on approximately $158.7 million underwritten public offering of 3,450,000 shares of common stock at a public offering
Simply Wall St.While institutions invested in Soleno Therapeutics, Inc. (NASDAQ:SLNO) benefited from last week's 4.8% gain, private equity firms stood to gain the most
Key Insights Significant control over Soleno Therapeutics by private equity firms implies that the general public has...
